Brexpiprazole
Also known as: Rxulti · Rexulti
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, brexpiprazole is indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. In the United States, it is indicated as an adjunctive treatment to antidepressants for major depressive disorder in adults, for the treatment of schizophrenia in adults and pediatric patients aged 13 years and older, and for the treatment of agitation associated with dementia due to Alzheimer's disease. It is not indicated in the United States as an as-needed treatment for agitation associated with dementia due to Alzheimer's disease.
From: Source: European Medicines Agency (EMA), Rxulti — EPAR, 29/07/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 1658314 brexpiprazole
- EMA
- EMEA/H/C/003841
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) Rexulti
1 INDICATIONS AND USAGE REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] . REXULTI is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults and pediatric patients ages 13 years and older ( 1 , 14.2 ) Treatment of agitation associated with dementia due to Alzheimer's disease ( 1 , 14.3 ) Limitations of Use : REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease ( 1 )
Data provided by the U.S. Food and Drug Administration.
Document date: 20260602 · Official document →
EMA (EU) Rxulti
Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older.
Source: European Medicines Agency (EMA), Rxulti — EPAR, 29/07/2026. © European Medicines Agency.
Document date: 29/07/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Schizophrenia Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Brexpiprazole approved for in the European Union?
Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older. (Source: European Medicines Agency (EMA), Rxulti — EPAR, 29/07/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Rxulti — EPAR, 29/07/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.